H.C. Wainwright analyst Edward White maintained a Buy rating on Clovis Oncology (CLVS) today and set a price target of $23.00. The company’s shares closed last Wednesday at $5.45.
According to TipRanks.com, White is a 5-star analyst with an average return of 20.9% and a 47.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.
Clovis Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $19.50.
See today’s analyst top recommended stocks >>
Based on Clovis Oncology’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $39.89 million and GAAP net loss of $92.25 million. In comparison, last year the company earned revenue of $32.98 million and had a GAAP net loss of $120 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
